Daver, N., Montesinos, P., Aribi, A., Marconi, G., Altman, J. K., Wang, E. S., … Sweet, K. (2022). Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). In Blood (Vol. 140, pp. 145–149). American Society of Hematology. https://doi.org/10.1182/blood-2022-158030

Daver, Naval, Pau Montesinos, Ahmed Aribi, Giovanni Marconi, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, et al. “Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” In Blood, 140:145–49. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-158030.

Daver N, Montesinos P, Aribi A, Marconi G, Altman JK, Wang ES, et al. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). In: Blood. American Society of Hematology; 2022. p. 145–9.

Daver, Naval, et al. “Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 145–49. Crossref, doi:10.1182/blood-2022-158030.

Daver N, Montesinos P, Aribi A, Marconi G, Altman JK, Wang ES, Roboz GJ, Burke PW, Gaidano G, Walter RB, Thomas X, Jeyakumar D, DeAngelo DJ, Erba HP, Todisco E, Begna KH, Advani A, Gastaud L, De La Fuente A, Curti A, Mendez LM, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwoerer S, Schliemann C, Konopleva M, Torres L, Sallman DA, Marcucci G, Pemmaraju N, Martinelli G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. American Society of Hematology; 2022. p. 145–149.